Expression and clinical application of aromatasecy P450 and receptor of estrogen and progesterone in the tissue of endometrial cancinoma

Objective:To study the expression of aromatasecy P450 and receptor of estrogen and progesterone in the tissue of endometrial hyperplasia and endometrial cancinoma,analysis the correlation of the endometrial carcinoma pathogenesis,clinical stage and cell differentiation.Methods:The immunohistochemiscal S-P method techniques were performed to study the expression of aromatasecy P450,estrogen receptor(ER) and progesterone receptor(PR) in the tissue of endometrium from 226 cases,including 42 cases of normal endometrium,52 cases of simple endometrial hyperplasia,38 cases of complex endometrial hyperplasia,36 cases of endometrial atypical hyperplasia and 58 cases of endometrial carcinoma.Results:There was no the positive expression in the normal endometrial tissues.But the positive expressions of aromatasecy P450 were found in the tissue of endometrial hyperplasia(simple endometrial hyperplasia,complex endometrial,atypical hyperplasia)and endometrial carcinoma.The rates of the positive expression were 40.4%,47.4%,69.4%,72.4% respectively.There were significant relationships among fifth groups(P0.01).The rates of the positive expressions of ER in the tissue of normal endometrial,endometrial hyperplasia(simple endometrial hyperplasia,complex endometrial,atypical hyperplasia)and endometrial carcinoma were 59.5%,61.5%,57.5%,61.1%,60.3%,.The rates of the PR were 73.8%,73.1%,73.7%,72.2%,74.1%.There were no relationship between the rates of the positive expressions of ER and PR and degree of the histological atypia.There were no relationship between the expressions rates of aromatasecy P450 and the expressions of ER and PR in endometrial hyperplasia and endometrial carcinoma.Conclusion:Aromatasecy P450 may be a factor that induces endometrial hyperplasia and carcinomatous changes.And it may become a biological marker in early carcinomatous changes in endometrial tissues.